EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer

Claudia Arndt iD, Irene García de Andres, Ralf Bergmann, Nicola Mitwasi, Christin Neuber iD, Karla E G Soto, Nathalia Jones-Cifuentes iD, Alexandra von Jutrzenka-Trzebiatowski iD, Liliana R Loureiro, Domokos Mathé iD, Michael Bachmann, Anja Feldmann

International Journal of Molecular Sciences · 18.07.2026 · 27 (14) · 6407

DOI: 10.3390/ijms27146407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.07.2026. Verfasst von Claudia Arndt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasm Proteins, Receptors, Chimeric Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, Government of Hungary, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) therapies are emerging as promising strategies, particularly for metastatic castration-resistant prostate cancer (PCa), as they can act independently of the androgen receptor axis. Adapter CAR-T cell platforms, such as the RevCAR system, offer precise therapeutic control and tumor targeting via small, rapidly eliminated tumor-specific adapters. To enable more convenient late-stage RevCAR-T therapy in PCa patients, allowing for discontinuous reverse target module (RevTM) infusion, we developed novel, larger IgG4-based RevTMs targeting prostate stem cell antigen (PSCA) and benchmarked them against previously described smaller adapter formats. Within the RevCAR system, PSCA-IgG4 RevTMs effectively mediated PCa killing at low effector-to-target ratios and low RevTM concentrations in a strictly antigen-dependent manner. Oncolytic activity was accompanied by a rapid and pronounced release of proinflammatory cytokines across a broad RevTM concentration range, which is particularly advantageous for immunologically cold PCa. Finally, anti-tumor activity was confirmed in a short-term mouse model. Preliminary PET studies further indicate slow blood elimination and tumor-specific accumulation of novel IgG4-RevTMs. Together, these data position PSCA-IgG4 RevTMs as promising candidates for stepwise RevCAR-T treatment in PCa, in which short-lived scFv-RevTMs are initially used to ensure a rapid safety switch, followed by larger IgG4-RevTMs once the risk profile is known.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasm ProteinsReceptors, Chimeric AntigenProstatic NeoplasmsImmunotherapy, AdoptiveProstatic Neoplasms, Castration-ResistantT-LymphocytesMaleHumansAnimalsMiceGPI-Linked ProteinsImmunoglobulin GCell Line, Tumor

Stichwörter der Autor:innen

CAR-T cellsPSCARevCARimmunotherapyprostate cancer

Substanzen

Antigens, NeoplasmPSCA protein, humanNeoplasm ProteinsReceptors, Chimeric AntigenGPI-Linked ProteinsImmunoglobulin G

Autor:innen und Institutionen

  • Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
  • Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany.
  • Department of Biophysics and Radiation Biology-HUN-REN TKI, Semmelweis University, H-1094 Budapest, Hungary.
  • Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, H-6723 Szeged, Hungary.
  • School of Medicine, Department of Basic Sciences, Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
  • German Cancer Consortium (DKTK), Partner Site Dresden, 01307 Dresden, Germany.

ORCID-Profile: Claudia Arndt, Christin Neuber, Nathalia Jones-Cifuentes, Alexandra von Jutrzenka-Trzebiatowski, Domokos Mathé

Förderung

  • German Cancer Aid
  • Government of Hungary
  • European Union
  • Helmholtz Association of German Research Centres
  • Hungarian Government
  • EU’s Horizon 2020 Research and Innovation Program
  • Helmholtz Initiative and Networking Fund
  • Helmholtz International Lab MHELTHERA

Zitieren

APA

Arndt, C., García de Andres, I., Bergmann, R., Mitwasi, N., Neuber, C., Soto, K. E. G., Jones-Cifuentes, N., von Jutrzenka-Trzebiatowski, A., Loureiro, L. R., Mathé, D., Bachmann, M., & Feldmann, A. (2026). Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer. International Journal of Molecular Sciences, 27(14), 6407. https://doi.org/10.3390/ijms27146407

Vancouver

Arndt C, García de Andres I, Bergmann R, Mitwasi N, Neuber C, Soto KEG, et al. Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer. International Journal of Molecular Sciences. 2026;27(14):6407. doi:10.3390/ijms27146407

BibTeX
@article{Arndt2026,
  author = {Arndt, Claudia and García de Andres, Irene and Bergmann, Ralf and Mitwasi, Nicola and Neuber, Christin and Soto, Karla E G and Jones-Cifuentes, Nathalia and von Jutrzenka-Trzebiatowski, Alexandra and Loureiro, Liliana R and Mathé, Domokos and Bachmann, Michael and Feldmann, Anja},
  title = {Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6407},
  doi = {10.3390/ijms27146407}
}
Kostenlos starten →